Evidence map›Paper›PMID 40905240›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2025

A Novel α-Synuclein K58N Missense Variant in a Patient with Parkinson's Disease.

Mohammed Al-Azzani, Sandrina Weber, Nagendran Ramalingam, Maria Ramón, Liana Shvachiy, Gonçalo Mestre, Michael Zech, Kevin Sicking, Alain Ibáñez de Opakua, Vidyashree Jayanthi and 15 more

Abstract readCase Reports
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. bioRxiv : the preprint server for biology · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Mohammed Al-AzzaniUniversity Medical Center Göttingen, Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Göttingen, Germany.ORCID https://orcid.org/0000-0003-2864-0854
Sandrina WeberDepartment of Neurology, University Medical Center Göttingen, Göttingen, Germany.ORCID https://orcid.org/0000-0001-5713-2141
Nagendran RamalingamAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-9459-3593
Maria RamónUniversity Medical Center Göttingen, Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Göttingen, Germany.
Liana ShvachiyUniversity Medical Center Göttingen, Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Göttingen, Germany.
Gonçalo MestreUniversity Medical Center Göttingen, Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Göttingen, Germany.
Michael ZechInstitute of Neurogenomics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.ORCID https://orcid.org/0000-0001-8112-9153
Kevin SickingUniversity Medical Center Göttingen, Institute for Neuropathology, Göttingen, Germany.
Alain Ibáñez de OpakuaGerman Center for Neurodegenerative Diseases, Göttingen, Germany.
Vidyashree JayanthiAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Leslie AmaralUniversity Medical Center Göttingen, Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Göttingen, Germany.
Aishwarya AgarwalCambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Aswathy ChandranCambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Susana R ChavesCBMA-Centre of Molecular and Environmental Biology, School of Sciences, University of Minho, Braga, Portugal.
Juliane WinkelmannInstitute of Neurogenomics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
Claudia TrenkwalderDepartment of Neurosurgery, University Medical Centre Göttingen, Göttingen, Germany.
Maike SchwagerInstitute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany.
Silke PauliInstitute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany.
Ulf DettmerAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Claudio O FernándezMax Planck Laboratory for Structural Biology, Chemistry and Molecular Biophysics of Rosario (MPLbioR, UNR-MPINAT), Partner Laboratory of the Max Planck Institute for Multidisciplinary Sciences (MPINAT, MPG). Centro de Estudios Interdisciplinarios, Universidad Nacional de Rosario, Rosario, Argentina.
Janin LautenschlägerCambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Markus ZweckstetterGerman Center for Neurodegenerative Diseases, Göttingen, Germany.
Ruben Fernandez-BusnadiegoUniversity Medical Center Göttingen, Institute for Neuropathology, Göttingen, Germany.
Brit MollenhauerDepartment of Neurology, University Medical Center Göttingen, Göttingen, Germany.ORCID https://orcid.org/0000-0001-8437-3645
Tiago Fleming OuteiroUniversity Medical Center Göttingen, Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Göttingen, Germany.

Funding

Elucidating the Biological Differences Between Distinct Fibrillar and Non-Fibrillar Alpha-Synuclein Inclusions in Human Stem-Cell ModelsR01NS109209 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI KHURANA, VIKRAM · 2020 to 2024
$4.5M
How Serine-129 Phosphorylation Status Affects the Spreading of α-Synuclein Pathology in Vivo: a Study in Knock-in AnimalsRF1NS133979 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI DETTMER, ULF, RAMALINGAM, NAGENDRAN · 2023 to 2023
$2.2M
Polo-like-kinase-2-dependent α-Synuclein Serine-129 Phosphorylation: a Physiological RoleDuring Synaptic ActivityRF1NS122880 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI DETTMER, ULF, RAMALINGAM, NAGENDRAN · 2022 to 2022
$2.1M
Stabilizing native α-synuclein homeostasis to prevent insoluble α-synuclein aggregatesR01NS099328 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI DETTMER, ULF · 2017 to 2021
$1.9M
Polo-like-kinase-2-dependent α-Synuclein Serine-129 Phosphorylation: a Physiological RoleDuring Synaptic ActivityR01NS122880 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI Ulf Dettmer, Nagendran Ramalingam · 2025 to 2026
$1.4M
Contrasting pathomechanisms of membrane versus cytosol alpha-synuclein excessR21NS121826 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI DETTMER, ULF · 2021 to 2021
$505k
Distinguishing α-Synuclein S129 Phosphorylation in Health and Lewy Body DementiaR21AG085401 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI Nagendran Ramalingam · 2024 to 2026
$433k
Addenbrooke's Charitable Trust 900325Deutsche Forschungsgemeinschaft EXC 2067/1- 390729940Deutsche Forschungsgemeinschaft SFB1286 (A12)Deutsche Forschungsgemeinschaft SFB1286 (B8)Else Kröner-Fresenius-Stiftung 2022_EKSE.185European Joint Programme on Rare Diseases, EJP RD Joint Transnational Call 2022German Federal Ministry of Education and Research 01GM2302Leverhulme Trust RPG-2022-257Michael J. Fox Foundation for Parkinson's Research MJFF-022411NIA NIH HHS R21 AG085401NIH HHS AG085401NIH HHS NS099328NIH HHS NS109209NIH HHS NS121826NIH HHS NS122880NINDS NIH HHS R01 NS099328NINDS NIH HHS R01 NS109209NINDS NIH HHS R01 NS122880NINDS NIH HHS R21 NS121826NINDS NIH HHS RF1 NS122880NINDS NIH HHS RF1 NS133979Royal Society DHF/R1/201228
6 · The paper itself

Abstract

backgroundParkinson's disease (PD) is a complex multifactorial disorder with a genetic component in about 15% of cases. Multiplications and point mutations in SNCA gene, encoding α-synuclein (aSyn), are linked to rare familial forms of PD.

objectiveOur goal was to assess the clinical presentation and the biological effects of a novel K58N aSyn mutation identified in a patient with PD.

methodsWe describe the clinical presentation associated with the novel mutation, together with genetic testing through whole exome sequencing (WES). Furthermore, we conducted extensive biophysical and cellular assays to assess the functional consequences of this novel variant.

resultsThe patient exhibited typical features of sporadic PD with early onset and a benign disease course. WES showed a novel heterozygous missense variant in SNCA (NM_000345.4, c.174G>C; p.K58N). A positive family history of PD was evident, because both a parent and a grandparent had been diagnosed with PD but were deceased. The patient underwent deep brain stimulation surgery 13 years postdiagnosis, showing stable, long-term improvements in motor symptoms. Biophysical studies demonstrated K58N substitution causes local structural effects, disrupts membrane binding, and enhances aSyn in vitro aggregation. In cellular systems, K58N aSyn produces fewer inclusions per cell and does not form condensates. The variant increases aSyn cytoplasmic distribution and displays aberrant activity-dependent dynamic serine-129 phosphorylation.

conclusionsThe clinical presentation associated with the novel K58N aSyn mutation suggests a relatively benign PD course consistent with the phenotypic spectrum of idiopathic PD. Overall, our molecular studies provide novel insight into the biology and pathobiology of aSyn. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

alpha-SynucleinMutation, MissenseParkinson DiseaseExome SequencingFemaleHumansMaleMiddle AgedPedigreealpha-SynucleinSNCA protein, humangeneticsneurodegenerationParkinson's diseaseprotein aggregationα‐synuclein

Identifiers

PMID40905240
PMCPMC12710137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.